| Literature DB >> 8769374 |
J P Moreau1, S Kim, J Z Dong, F Ignatious, S Jackson, S C Moreau, B A Morgan, F Touraud, J E Taylor, B Tissier, M Pellet, W Murphy, T Davis.
Abstract
Appropriate N-terminus modification can result in somatostatin (SRIF) octapeptide analogs that are both more potent and more selective in vitro for the human SRIF receptor type 2 (hsst2). In addition, these modifications can improve the duration of action and bioavailability of SRIF analogs following parenteral administration, as shown by both pharmacological and distribution studies in vivo with BIM-23190 and BIM-23197 in the rat.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8769374 DOI： 10.1016/s0026-0495(96)90074-8
Source DB: PubMed Journal: Metabolism ISSN： 0026-0495 Impact factor: 8.694